Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

5/18 Late treatment study

Horby et al., medRxiv, doi:10.1101/2021.05.18.21257267 (Preprint)
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Source PDF Share Tweet

RCT with 5,610 colchicine and 5,730 control patients showing mortality RR 1.01 [0.93-1.10]. Very late stage treatment, mean 9 days after symptom onset. Baseline oxygen requirements unknown (data is provided but combined with "none"). ISRCTN 50189673. NCT04381936.

Horby et al., 5/18/2021, Randomized Controlled Trial, United Kingdom, Europe, preprint, 35 authors.

risk of death, 1.0% higher, RR 1.01, p = 0.77, treatment 1173 of 5610 (20.9%), control 1190 of 5730 (20.8%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 10 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit